News

STAT2d
How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition
A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...
STAT3d
Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...